DOCSLIB.ORG

Alder Biopharmaceuticals, Inc. (Exact Name of Registrant As Specified in Its Charter)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Alder Biopharmaceuticals, Inc. (Exact Name of Registrant As Specified in Its Charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36431 Alder BioPharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 90-0134860 (State or other jurisdiction (I.R.S. Employer of incorporation or organization) Identification No.) 11804 North Creek Parkway South Bothell, WA 98011 (Address of principal executive offices including zip code) Registrant’s telephone number, including area code: (425) 205-2900 Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. Large accelerated filer ☒ Accelerated filer ☐ Non-accelerated filer ☐ Smaller reporting company ☐ Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒ As of April 25, 2019, the registrant had 83,503,820 shares of common stock, $0.0001 par value per share, outstanding. Securities registered pursuant to Section 12(b) of the Act: Title of Each Class Trading Symbol(s) Name of Exchange on Which Registered Common Stock, $0.0001 par value per share ALDR The Nasdaq Stock Market LLC (The Nasdaq Global Market) Alder BioPharmaceuticals, Inc. Quarterly Report on Form 10-Q For the Quarter Ended March 31, 2019 INDEX Page PART I. FINANCIAL INFORMATION (Unaudited) Item 1. Condensed Consolidated Financial Statements 3 Condensed Consolidated Balance Sheets 3 Condensed Consolidated Statements of Operations 4 Condensed Consolidated Statements of Comprehensive Loss 5 Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders’ Equity 6 Condensed Consolidated Statements of Cash Flows 7 Notes to Condensed Consolidated Financial Statements 8 Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 24 Item 3. Quantitative and Qualitative Disclosures About Market Risk 35 Item 4. Controls and Procedures 36 PART II. OTHER INFORMATION Item 1. Legal Proceedings 37 Item 1A. Risk Factors 37 Item 6. Exhibits 66 SIGNATURES 68 In this Quarterly Report on Form 10-Q, “we,” “our,” “us,” “Alder,” and “the Company” refer to Alder BioPharmaceuticals, Inc. and, where appropriate, its consolidated subsidiaries. “Alder,” “Alder BioPharmaceuticals” and the Alder logo are the property of Alder BioPharmaceuticals, Inc. This report contains references to our trademarks and trade names and to trademarks belonging to other entities. Solely for convenience, trademarks and trade names referred to in this report may appear without the ® or ™ symbols, but such references are not intended to indicate, in any way, that their respective owners will not assert, to the fullest extent under applicable law, their rights thereto. We do not intend our use or display of other companies’ trade names or trademarks to imply a relationship with, or endorsement or sponsorship of us by, any other companies. 2 PART I. – FINANCIAL INFORMATION Item 1. Condensed Consolidated Financial Statements Alder BioPharmaceuticals, Inc. Condensed Consolidated Balance Sheets (unaudited) March 31, December 31, 2019 2018 (in thousands, except share and per share data) Assets Current assets Cash and cash equivalents $ 126,105 $ 87,865 Short-term investments 348,517 319,504 Restricted cash 23,886 5,000 Prepaid expenses and other assets 3,806 7,440 Total current assets 502,314 419,809 Property and equipment, net 6,149 6,400 Right of use assets 4,693 — Other assets 12 30 Total assets $ 513,168 $ 426,239 Liabilities, convertible preferred stock and stockholders’ equity Current liabilities Accounts payable $ 15,316 $ 8,945 Accrued liabilities 42,687 19,217 Accrued dividends on convertible preferred stock 1,311 — Operating lease liability 946 — Deferred rent — 74 Total current liabilities 60,260 28,236 Long-term operating lease liability 4,321 — Long-term deferred rent — 510 2025 convertible senior notes, net 185,146 182,104 Derivative liability 2,633 1,658 Total liabilities 252,360 212,508 Commitments and contingencies Class A-1 convertible preferred stock; $0.0001 par value; 10,000,000 shares authorized; 760,753 shares and no shares issued and outstanding, respectively; liquidation preference of $100,000 and zero, respectively 103,755 103,755 Stockholders’ equity Common stock; $0.0001 par value; 200,000,000 shares authorized; 83,246,074 and 68,410,576 shares issued and outstanding, respectively 8 7 Additional paid-in capital 1,239,411 1,074,963 Accumulated deficit (1,081,872) (963,938) Accumulated other comprehensive loss (494) (1,056) Total stockholders’ equity 157,053 109,976 Total liabilities, convertible preferred stock and stockholders’ equity $ 513,168 $ 426,239 The accompanying notes are an integral part of these condensed consolidated financial statements. 3 Alder BioPharmaceuticals, Inc. Condensed Consolidated Statements of Operations (unaudited) Three Months Ended March 31, 2019 2018 (in thousands, except share and per share data) Revenues Collaboration and license agreements $ — $ — Operating expenses Research and development 69,589 74,048 General and administrative 44,498 11,553 Total operating expenses 114,087 85,601 Loss from operations (114,087) (85,601) Other income (expense) Interest income 1,966 1,643 Interest expense (4,838) (2,851) Change in fair value of derivative liability (975) — Total other income (expense), net (3,847) (1,208) Net loss before equity in net loss of unconsolidated entity (117,934) (86,809) Equity in net loss of unconsolidated entity — (222) Net loss $ (117,934) $ (87,031) Deemed dividends on convertible preferred stock attributable to accretion of beneficial conversion feature — (29,460) Dividends on convertible preferred stock (1,311) (1,083) Net loss applicable to common stockholders $ (119,245) $ (117,574) Net loss per share applicable to common stockholders - basic and diluted $ (1.63) $ (1.73) Weighted average number of common shares used in net loss per share - basic and diluted 73,056,907 67,844,872 The accompanying notes are an integral part of these condensed consolidated financial statements. 4 Alder BioPharmaceuticals, Inc. Condensed Consolidated Statements of Comprehensive Loss (unaudited) Three Months Ended March 31, 2019 2018 (in thousands) Net loss $ (117,934) $ (87,031) Other comprehensive income (loss): Unrealized gain (loss) on securities available-for-sale, net of tax 562 (877) Total other comprehensive income (loss), net 562 (877) Comprehensive loss $ (117,372) $ (87,908) The accompanying notes are an integral part of these condensed consolidated financial statements. 5 Alder BioPharmaceuticals, Inc. Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders’ Equity (unaudited) Class A-1 Convertible Preferred Stock Common Stock Accumulated Additional Other Total Paid-in Accumulated Comprehensive Stockholders' Shares Amount Shares Amount Capital Deficit Income (Loss) Equity (in thousands, except for share data) Balances at December 31, 2017 — — 67,842,942 7 946,869 (667,509) (92) 279,275 Net loss — — — — — (87,031) — (87,031) Accrued dividends on convertible preferred stock — — — — (1,083) — — (1,083) Other comprehensive loss — — — — — — (877) (877) Issuance of Class A-1 convertible preferred stock, net of issuance costs of $2.3 million 725,268 97,710 — — — — — — Beneficial conversion feature on Class A-1 convertible preferred stock — (29,460) — — 29,460 — — 29,460 Deemed dividend on convertible preferred stock attributable to accretion of beneficial conversion feature — 29,460 — — (29,460) — — (29,460) Equity component of 2025 convertible senior notes — — — — 109,911 — — 109,911 Equity component of deferred financing costs for 2025 convertible senior notes — — — — (3,763) — — (3,763) Exercise of stock options — — 5,759 — 20 — — 20 Stock-based compensation — — — — 5,946 — — 5,946 Balances at March 31, 2018 725,268 $ 97,710 67,848,701 $ 7 $ 1,057,900 $ (754,540) $ (969) $ 302,398 Balances at December 31, 2018 760,753 $ 103,755 68,410,576 $ 7 $ 1,074,963 $ (963,938) $ (1,056) $ 109,976 Net loss — — — — — (117,934) — (117,934) Accrued dividends on convertible preferred stock — —
Load more

Recommended publications
  • Pharmacokinetics, Pharmacodynamics and Drug
    pharmaceutics Review Pharmacokinetics, Pharmacodynamics and Drug–Drug Interactions of New Anti-Migraine Drugs—Lasmiditan, Gepants, and Calcitonin-Gene-Related Peptide (CGRP) Receptor Monoclonal Antibodies Danuta Szkutnik-Fiedler Department of Clinical Pharmacy and Biopharmacy, Pozna´nUniversity of Medical Sciences, Sw.´ Marii Magdaleny 14 St., 61-861 Pozna´n,Poland; [email protected] Received: 28 October 2020; Accepted: 30 November 2020; Published: 3 December 2020 Abstract: In the last few years, there have been significant advances in migraine management and prevention. Lasmiditan, ubrogepant, rimegepant and monoclonal antibodies (erenumab, fremanezumab, galcanezumab, and eptinezumab) are new drugs that were launched on the US pharmaceutical market; some of them also in Europe. This publication reviews the available worldwide references on the safety of these anti-migraine drugs with a focus on the possible drug–drug (DDI) or drug–food interactions. As is known, bioavailability of a drug and, hence, its pharmacological efficacy depend on its pharmacokinetics and pharmacodynamics, which may be altered by drug interactions. This paper discusses the interactions of gepants and lasmiditan with, i.a., serotonergic drugs, CYP3A4 inhibitors, and inducers or breast cancer resistant protein (BCRP) and P-glycoprotein (P-gp) inhibitors. In the case of monoclonal antibodies, the issue of pharmacodynamic interactions related to the modulation of the immune system functions was addressed. It also focuses on the effect of monoclonal antibodies on expression of class Fc gamma receptors (FcγR). Keywords: migraine; lasmiditan; gepants; monoclonal antibodies; drug–drug interactions 1. Introduction Migraine is a chronic neurological disorder characterized by a repetitive, usually unilateral, pulsating headache with attacks typically lasting from 4 to 72 h.
    [Show full text]
  • Pharmacy Prior Authorization Grid ALTCS, and Pharmacy
    Please Note: Refer to the other PA grids for applicable covered services that require PA. PA Grids: Medical, Behavioral Health, Pharmacy Prior Authorization Grid ALTCS, and Pharmacy. (Effective Date of Service 1/1/2021) Injectables that require Prior Authorization All chemotherapeutic drugs must be used for FDA-approved indications and/or in accordance with NCCN guidelines *Indicates prior authorization required if billed charges are greater than $400 PA Required HMO 13 HCPCS Short Description (BUCA- Code SNP) 90378 Respiratory Syncytial Virus Immune Globulin Yes C9036 Patisiran Yes C9047 Caplacizumab-yhdp Yes C9061 Teprotumumab-trbw Yes C9063 Eptinezumab-jjmr Yes C9131 Factor VIII antihemophilic factor pegylated-auci Yes C9132 Prothrombin Complex Concentrate (Human), Kcentra Yes C9133 Factor IX (Antihemophilic Factor, Recombinant), Rixibus Yes C9399 Mipomersen (Kynamro) Yes J0129 Abatacept Yes J0135 Adalimumab Yes J0178 Aflibercept Yes J0179 Brolucizumab-dbll, 1 mg Yes J0180 Agalsidase Beta Yes J0205 Alglucerase Yes J0215 Alefacept Yes J0220 Alglucosidase Alfa (Myozyme) Yes J0221 Alglucosidase Alfa (Lumizyme) Yes J0222 Patisiran, 0.1 mg Yes J0223 Givosiran 0.5 mg Yes J0256 Alpha 1-Proteinase Inhibitor Yes J0257 Alpha 1-Proteinase Inhibitor (Glassia) Yes J0275 Alprostadil Urethral Suppository Yes J0490 Belimumab Yes J0517 Benralizumab Yes J0567 Cerliponase alfa Yes J0570 Buprenorphine implant Yes J0584 Burosumab-twza 1 mg Yes J0585 Onabotulinumtoxina (Botox) Yes J0586 Abobotulinumtoxina (Dysport) Yes J0587 Rimabotulinumtoxinb (Myobloc)
    [Show full text]
  • Oxford Policy Update Bulletin: April 2020
    Oxford April 2020 policy update bulletin Medical & Administrative Policy Updates Take Note POLICY IMPLEMENTATION DELAYED Implementation of the changes associated with the following Clinical Policies, previously announced for an effective date on or after Apr. 1, 2020, has been delayed as noted below: Policy Title Status Effective Date Genitourinary Pathogen Nucleic Acid Detection Panel Testing New May 1, 2020 Jun. 1, 2020 Outpatient Surgical Procedures - Site of Service Revised Apr. 6, 2020 TBD Tysabri® (Natalizumab) New Apr. 1, 2020 Jul. 1, 2020 Access a policy listed below for complete details on the latest updates. A comprehensive summary of changes is provided at the bottom of every policy document for your reference. To view a detailed version of this bulletin, click here. Policy Title Status Effective Date CLINICAL POLICY Abnormal Uterine Bleeding and Uterine Fibroids Revised Jun. 1, 2020 Actemra® (Tocilizumab) Injection for Intravenous Infusion Revised May 1, 2020 Adakveo® (Crizanlizumab-Tmca) Updated Apr. 1, 2020 Adakveo® (Crizanlizumab-Tmca) Revised Jul. 1, 2020 Cell-Free Fetal DNA Testing Revised Jun. 1, 2020 Cimzia® (Certolizumab Pegol) New Jul. 1, 2020 Collagen Crosslinks and Biochemical Markers of Bone Turnover Revised May 1, 2020 Drug Coverage Criteria – New and Therapeutic Equivalent Medications Revised May 1, 2020 Drug Coverage Guidelines Revised Apr. 1, 2020 Adakveo (Crizanlizumab-Tmca) Givlaari (Givosiran) Ziextenzo (Pegfilgrastim-Bmez) Drug Coverage Guidelines Revised May 1, 2020 Adlyxin (Lixisenatide) Arnuity
    [Show full text]
  • VYEPTI™ (EPTINEZUMAB) Policy Number: CSLA2020D0090A Effective Date: TBD
    Proprietary Information of United Healthcare: The information contained in this document is proprietary and the sole property of United HealthCare Services, Inc. Unauthorized copying, use and distribution of this information are strictly prohibited. Copyright 2020 United HealthCare Services, Inc. UnitedHealthcare® Community Plan Medical Benefit Drug Policy VYEPTI™ (EPTINEZUMAB) Policy Number: CSLA2020D0090A Effective Date: TBD Table of Contents Page Commercial Policy APPLICATION ...................................................... 1 Vyepti™ (Eptinezumab) COVERAGE RATIONALE ........................................ 1 APPLICABLE CODES ............................................. 2 BACKGROUND ................................................... 43 CLINICAL EVIDENCE ............................................ 4 U.S. FOOD AND DRUG ADMINISTRATION ............ 54 CENTERS FOR MEDICARE AND MEDICAID SERVICES 54 REFERENCES ....................................................... 5 POLICY HISTORY/REVISION INFORMATION ...... 65 INSTRUCTIONS FOR USE .................................... 65 APPLICATION This Medical Benefit Drug Policy only applies to state of Louisiana. COVERAGE RATIONALE Vyepti has been added to the Review at Launch program. Please reference the Medical Benefit Drug Policy titled Review at Launch for New to Market Medications for additional details. Chronic Migraine Vyepti is proven and medically necessary for the preventive treatment of chronic migraines when all of the following criteria are met: For initial therapy, all of the
    [Show full text]
  • 761119Orig1s000 SUMMARY REVIEW
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 761119Orig1s000 SUMMARY REVIEW Summary Review Summary Review Date February 21, 2020 Heather Fitter, MD From Nick Kozauer, MD Billy Dunn, MD Subject Summary Review BLA # 761119 Applicant Lundbeck Seattle BioPharmaceuticals, Inc. Date of Submission December 26, 2018 PDUFA Goal Date February 21, 2020 Proprietary Name Vyepti Established or Proper Names Eptinezumab Solution for intravenous (IV) injection (100 Dosage Form mg/mL) Applicant Proposed Prevention of migraine in adults Indication/Population 100 mg IV infusion every 3 months; 300 mg IV Applicant Proposed Dosing Regimen(s) infusion every 3 months Recommendation on Regulatory Action Approval Recommended Indication/Population Preventive treatment of migraine in adults 100 mg IV infusion every 3 months; 300 mg IV Recommended Dosing Regimen(s) infusion every 3 months 1 Reference ID: 4564908 Summary Review 1. Benefit-Risk Assessment Benefit-Risk Assessment Framework Benefit-Risk Integrated Assessment Eptinezumab is a humanized monoclonal antibody that binds to the calcitonin gene-related peptide (CGRP) ligand, and prevents CGRP binding to its receptor. The applicant provided information supporting safety and efficacy in patients with both chronic migraine (i.e., at least 15 headache days/month, with features of migraine headache on at least 8 days/month) and episodic migraine (i.e., up to 14 migraine headache days/month). There are several FDA-approved drugs for the preventive treatment of migraine. Three drugs in the anti-CGRP class were approved recently for this indication: erenumab (May 2018), fremanezumab (September 2018), and galcanezumab (September 2018). These three drugs are given by subcutaneous (SC) administration either monthly or quarterly, while eptinezumab is given intravenously (IV) quarterly.
    [Show full text]
  • (CGRP) Inhibitor Criteria – Migraine and Cluster Headache Prevention Approval Date: February 24, 2021
    New Hampshire Medicaid Fee-for-Service Program Calcitonin Gene-Related Peptide (CGRP) Inhibitor Criteria – Migraine and Cluster Headache Prevention Approval Date: February 24, 2021 Medications Brand Names Generic Names Dosage 70 mg/mL solution single-dose prefilled syringe or auto-injector; Aimovig® erenumab-aooe 140 mg/mL prefilled syringe and autoinjector 225 mg/1.5 mL solution single-dose prefilled syringe; Ajovy® fremanezumab-vfrm 225 mg/1.5 mL autoinjector 120 mg/mL solution single-dose prefilled syringe or prefilled pen; Emgality® galcanezumab-gnlm 100 mg/mL solution single-dose prefilled syringe Vyepti™ eptinezumab-jjmr Intravenous (IV) solution: 100 mg/mL Indication Aimovig® (erenumab-aooe): A high-affinity human immunoglobulin G2 (IgG2) monoclonal antibody that targets the calcitonin gene-related peptide (CGRP) receptor, is indicated for the preventative treatment of migraine in adults. Ajovy® (fremanezumab-vfrm): A human IgG2 monoclonal antibody that targets the CGRP receptor, is indicated for the preventative treatment of migraine in adults. Emgality® (galcanezumab-gnlm): A human immunoglobulin IgG4 monoclonal antibody that targets the CGRP ligand, is indicated for the preventative treatment of migraine and episodic cluster headaches in adults. Vyepti™ (eptinezumab-jjmr): A humanized immunoglobulin G1 (IgG1) monoclonal antibody that targets the CGRP ligand and inhibits its interaction with the receptor, is indicated for the preventative treatment of migraine in adults. Proprietary & Confidential © 2003–2021 Magellan Health, Inc. All rights reserved. Magellan Medicaid Administration, part of the Magellan Rx Management division of Magellan Health, Inc. Migraine Headache Prevention Request Criteria for Approval 1. Patient has a diagnosis of migraine with or without aura based on International Classification of Headache Disorders (ICHD-III) diagnostic criteria; AND 2.
    [Show full text]
  • Monoclonal Antibodies As Neurological Therapeutics
    pharmaceuticals Review Monoclonal Antibodies as Neurological Therapeutics Panagiotis Gklinos 1 , Miranta Papadopoulou 2, Vid Stanulovic 3, Dimos D. Mitsikostas 4 and Dimitrios Papadopoulos 5,6,* 1 Department of Neurology, KAT General Hospital of Attica, 14561 Athens, Greece; [email protected] 2 Center for Clinical, Experimental Surgery & Translational Research, Biomedical Research Foundation of the Academy of Athens (BRFAA), 11527 Athens, Greece; [email protected] 3 Global Pharmacovigilance, R&D Sanofi, 91385 Chilly-Mazarin, France; vid.stanulovic@sanofi.com 4 1st Neurology Department, Aeginition Hospital, National and Kapodistrian University of Athens, 11521 Athens, Greece; [email protected] 5 Laboratory of Molecular Genetics, Hellenic Pasteur Institute, 129 Vasilissis Sophias Avenue, 11521 Athens, Greece 6 Salpetriere Neuropsychiatric Clinic, 149 Papandreou Street, Metamorphosi, 14452 Athens, Greece * Correspondence: [email protected] Abstract: Over the last 30 years the role of monoclonal antibodies in therapeutics has increased enormously, revolutionizing treatment in most medical specialties, including neurology. Monoclonal antibodies are key therapeutic agents for several neurological conditions with diverse pathophysio- logical mechanisms, including multiple sclerosis, migraines and neuromuscular disease. In addition, a great number of monoclonal antibodies against several targets are being investigated for many more neurological diseases, which reflects our advances in understanding the pathogenesis of these
    [Show full text]
  • Vyepti® (Eptinezumab-Jjmr) (Intravenous) Document Number: MAYO-0527 Last Review Date: 10/01/2020 Date of Origin: 04/01/2020 Dates Reviewed: 04/2020, 10/2020
    Vyepti® (eptinezumab-jjmr) (Intravenous) Document Number: MAYO-0527 Last Review Date: 10/01/2020 Date of Origin: 04/01/2020 Dates Reviewed: 04/2020, 10/2020 I. Length of Authorization Coverage will be provided for six months and may be renewed. II. Dosing Limits A. Quantity Limit (max daily dose) [NDC Unit]: • Vyepti 100 mg/mL solution SDV: 3 vials per 84 days B. Max Units (per dose and over time) [HCPCS Unit]: − 300 billable units every 84 days III. Initial Approval Criteria 1 Coverage is provided in the following conditions: Universal Criteria 1,4-8 • Other causes of headaches have been ruled out; AND • Not used in combination with other calcitonin gene-related peptide (CGRP) antagonists (e.g., erenumab, galcanezumab, fremanezumab, etc.) §; AND • Patient will continue to utilize prophylactic intervention modalities (i.e., pharmacotherapy, behavioral therapy, physical therapy, etc.); AND • Physician has assessed baseline disease severity utilizing an objective measure/tool (e.g., Headache Impact Test [HIT]; monthly headache day [MHD]; Migraine Disability Assessment [MIDAS]; Migraine Physical Function Impact Diary [MPFID]); AND • Patient has failed at least an 8-week trial of any two oral medications for the prevention of migraines (see list of prophylactic medications below for examples) prior to initiation of eptinezumab; AND • Failure of or contraindication to use of a self-injected, prophylactic calcitonin gene-related peptide (CGRP) antagonists; AND § Note: Use with acute CGRP therapies (e.g., ubrogepant) is allowed Proprietary &
    [Show full text]
  • Anti‐Migraine Calcitonin Gene–Related Peptide Receptor
    RESEARCH ARTICLE Anti-migraine Calcitonin Gene–Related Peptide Receptor Antagonists Worsen Cerebral Ischemic Outcome in Mice † † Inge A. Mulder, MSc ,1 Mei Li, PhD,1 Tessa de Vries, MSc,2 Tao Qin,1 , Takeshi Yanagisawa, MD, PhD,1 Kazutaka Sugimoto, MD, PhD ,1 Antoon van den Bogaerdt, PhD,3 A. H. Jan Danser, MD, PhD,2 Marieke J. H. Wermer, MD, PhD,4 Arn M. J. M. van den Maagdenberg, PhD,4,5 ‡ Antoinette MaassenVanDenBrink, PhD,2 Michel D. Ferrari, MD, PhD,4 and ‡ Cenk Ayata, MD, PhD1,6 Objective: Calcitonin gene–related peptide (CGRP) pathway inhibitors are emerging treatments for migraine. CGRP- mediated vasodilation is, however, a critical rescue mechanism in ischemia. We, therefore, investigated whether gepants, small molecule CGRP receptor antagonists, worsen cerebral ischemia. Methods: Middle cerebral artery was occluded for 12 to 60 minutes in mice. We compared infarct risk and volumes, collateral flow, and neurological deficits after pretreatment with olcegepant (single or 10 daily doses of 0.1–1mg/kg) or rimegepant (single doses of 10–100mg/kg) versus vehicle. We also determined their potency on CGRP-induced relaxa- tions in mouse and human vessels, in vitro. Results: Olcegepant (1mg/kg, single dose) increased infarct risk after 12- to 20-minute occlusions mimicking transient ischemic attacks (14/19 vs 6/18 with vehicle, relative risk = 2.21, p < 0.022), and doubled infarct volumes (p < 0.001) and worsened neurological deficits (median score = 9 vs 5 with vehicle, p = 0.008) after 60-minute occlusion. Ten daily doses of 0.1 to 1mg/kg olcegepant yielded similar results.
    [Show full text]
  • CDER List of Licensed Biological Products With
    Center for Drug Evaluation and Research List of Licensed Biological Products with (1) Reference Product Exclusivity and (2) Biosimilarity or Interchangeability Evaluations to Date DATE OF FIRST REFERENCE PRODUCT DATE OF LICENSURE LICENSURE EXCLUSIVITY EXPIRY DATE INTERCHANGEABLE (I)/ BLA STN PRODUCT (PROPER) NAME PROPRIETARY NAME (mo/day/yr) (mo/day/yr) (mo/day/yr) BIOSIMILAR (B) WITHDRAWN 125118 abatacept Orencia 12/23/05 NA NA 103575 abciximab ReoPro 12/22/94 NA NA Yes 125274 abobotulinumtoxinA Dysport 04/29/09 125057 adalimumab Humira 12/31/02 NA NA 761071 adalimumab-adaz Hyrimoz 10/30/18 B 761058 adalimumab-adbm Cyltezo 08/25/17 B 761118 adalimumab-afzb Abrilada 11/15/19 B 761024 adalimumab-atto Amjevita 09/23/16 B 761059 adalimumab-bwwd Hadlima 07/23/19 B 125427 ado-trastuzumab emtansine Kadcyla 02/22/13 125387 aflibercept Eylea 11/18/11 103979 agalsidase beta Fabrazyme 04/24/03 NA NA 125431 albiglutide Tanzeum 04/15/14 017835 albumin chromated CR-51 serum Chromalbin 02/23/76 103293 aldesleukin Proleukin 05/05/92 NA NA 103948 alemtuzumab Campath, Lemtrada 05/07/01 NA NA 125141 alglucosidase alfa Myozyme 04/28/06 NA NA 125291 alglucosidase alfa Lumizyme 05/24/10 125559 alirocumab Praluent 07/24/15 103172 alteplase, cathflo activase Activase 11/13/87 NA NA 103950 anakinra Kineret 11/14/01 NA NA 020304 aprotinin Trasylol 12/29/93 125513 asfotase alfa Strensiq 10/23/15 101063 asparaginase Elspar 01/10/78 NA NA 125359 asparaginase erwinia chrysanthemi Erwinaze 11/18/11 761034 atezolizumab Tecentriq 05/18/16 761049 avelumab Bavencio 03/23/17
    [Show full text]
  • CGRP Inhibitors
    MEDICATION POLICY: CGRP Inhibitors Generic Name: N/A Preferred: Ajovy (fremanezumab-vfrm) Therapeutic or Brand Name: Calcitonin Gene- Non-preferred: Aimovig (Erenumab-aooe), Related Peptide (CGRP) Inhibitors Emgality (galcanezumab-gnlm), Nurtec (rimegepant), Ubrelvy (ubrogepant), Vypeti Applicable Drugs (if Therapeutic Class): (eptinezumab-jjmr) AimovigTM (Erenumab-aooe), AjovyTM (fremanezumab-vfrm), Emgality™ Date of Origin: 10/2/2018 (galcanezumab-gnlm), NurtecTM (rimegepant), Date Last Reviewed / Revised: 2/11/2021 Ubrelvy TM (ubrogepant), Vypeti TM (eptinezumab-jjmr) GPI Code: 6770202010, 6770203020, 6770203530, 6740654060, 6770108000, 6770201520 PRIOR AUTHORIZATION CRITERIA (May be considered medically necessary when criteria I through V are met) I. Documented diagnosis of one of the following conditions A or B and must meet criteria listed under applicable diagnosis: A. Episodic migraine headaches (4-14 migraine days per month) or chronic migraines (15 or more headache days per month with at least 8 migraine days per month) and criteria i – IV. Is met: i. Documentation of functional impairment due to episodic or chronic migraines (eg, severe pain, missed days at school or work, impaired activities of daily living). ii. Documentation of treatment failure, intolerance, or contraindication to medications from all 3 of the following drug categories A through C for prevention of episodic or chronic migraine headaches: 1. Anticonvulsants (such as Divalproex Sodium or Topiramate) 2. Beta-blockers (such as Metoprolol or propranolol) 3. Antidepressants (such as Venlafaxine or Amitriptyline) iii. Documentation that evaluation has been performed demonstrating patient does not suffer from rebound headaches due to medication overuse (medication overuse headache, or MOH). iv. Prescription is for Ajovy OR there is a clinically significant treatment failure, intolerance or contraindication to Ajovy and the prescription is for Aimovig, Emgality, or Vyepti.
    [Show full text]
  • Umpqua Health Alliance List of Medication Coverage Changes
    Umpqua Health Alliance List of Medication Coverage Changes (Updated 4/1/2021) INTRODUCTION The Umpqua Health Alliance (UHA) Pharmacy and Therapeutics (P&T) Committee composed of pharmacists and physicians determine which drugs should be covered, the coverage restrictions, and the PA guidelines. The goal of the P&T Committee is to create a formulary (list of covered drugs) with medications that are safe and effective and that offer the best value. Our formulary and prior authorization guidelines are usually updated quarterly. This document contains all updates made to the UHA formulary and PA guidelines since January 1, 2020. The current versions of our formulary and PA guidelines are available on the UHA Pharmacy Services webpage: https://www.umpquahealth.com/pharmacy‐services/. LEGEND The following are restriction and coverage abbreviations found in this document: ABBREVIATIONS DEFINITION EXPLANATION PA Prior Authorization Required Prior authorization (e.g. prior approval) is required before filling a prescription for this drug. Without prior authorization, we may not cover this drug. The provider must submit a request for prior authorization with the appropriate documentation (including recent chart notes) before the drug is covered. A specific PA guideline policy number beginning with “RX” may be referenced in the “Description” column. Visit the UHA Pharmacy Services webpage for our PA guidelines: https://www.umpquahealth.com/pharmacy‐services/. ST Step Therapy Restriction We require trial and failure of one or more lower‐cost or preferred drug(s) (“Step 1 drug”) before using the more expensive or non‐preferred drug (“Step 2 drug”). If it is medically necessary for a member to use a Step 2 drug first, the prescriber will need to submit a request for prior authorization.
    [Show full text]